75 patents currently held
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Nov 2027. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
10
Ending by 2030
Nov 2027
Next term end
33
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jan 2028 · High confidence
Also notable
Ends Nov 2031 · High confidence
Also notable
Ends Sep 2033 · High confidence
Devices and Methods for Glaucoma Treatment
US 9,597,230
Cited by 241 later US patents, top 1% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2028.
Controlled Drug Delivery Ocular Implants and Methods of Using Same
US 11,253,394
Cited by 59 later US patents, top 5% of utility patents granted in 2022 in our data. Protection runs to 2031.
System and Method for Delivering Multiple Ocular Implants
US 11,197,780
Cited by 56 later US patents, top 5% of utility patents granted in 2021 in our data. Protection runs to 2033. A terminal disclaimer caps this term to an earlier patent's.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 18, 2027The maintenance fee for Intraocular Physiological Sensor (US 11,701,019) comes due Jan 18, 2027. Unpaid by Jul 19, 2027, it lapses early.
- 1 fee due Mar 5, 2027The maintenance fee for Gonioscopes (US 11,744,458) comes due Mar 5, 2027. Unpaid by Sep 7, 2027, it lapses early.
- 2 fees due May 3 to 28, 2027 · next May 3
- 2 fees due Jun 10 to 30, 2027 · next Jun 10
- 2 fees due Jul 2 to 16, 2027 · next Jul 2
- 1 fee due Sep 12, 2027The maintenance fee for Drug Delivery Implants with Bi-Directional Delivery Capacity (US 11,925,578) comes due Sep 12, 2027. Unpaid by Mar 13, 2028, it lapses early.
- 1 fee due Oct 2, 2027The maintenance fee for System and Method for Delivering Multiple Ocular Implants (US 11,944,573) comes due Oct 2, 2027. Unpaid by Apr 3, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The 5 largest of its 33 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Drug Eluting Ocular Implant | 12 in force | to Mar 2034 |
| Gonioscopic Devices | 5 in force | to Jun 2036 |
| System for Delivering Multiple Ocular Implants | 5 in force | to Jan 2034 |
| Uveoscleral Shunt and Methods for Implanting Same | 4 in force | to Feb 2029 |
| Implant Delivery Apparatus | 3 in force | to Dec 2036 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,962,290 | Uveoscleral Shunt and Methods for Implanting Same In force · High confidence | In force | High confidence | |
| US 10,828,195 | Uveoscleral Shunt and Methods for Implanting Same In force · High confidence | In force | High confidence | |
| US 12,186,237 | Uveoscleral Shunt and Methods for Implanting Same In force · High confidence | In force | High confidence | |
| US 9,597,230 | Devices and Methods for Glaucoma Treatment In force · High confidence | In force | High confidence | |
| US 9,561,131 | Implant Delivery System and Methods Thereof for Treating Ocular Disorders In force · Medium confidence | In force | Medium confidence | |
| US 8,506,515 | Uveoscleral Shunt and Methods for Implanting Same In force · High confidence | In force | High confidence | |
| US 12,376,989 | Drug Eluting Ocular Implants and Methods of Treating an Ocular Disorder In force · High confidence | In force | High confidence | |
| US 12,478,504 | Drug Eluting Ocular Implants In force · High confidence | In force | High confidence | |
| US 12,201,557 | Drug Eluting Ocular Implant and Method of Treating an Ocular Disorder In force · High confidence | In force | High confidence | |
| US 10,206,813 | Implants with Controlled Drug Delivery Features and Methods of Using Same In force · High confidence | In force | High confidence |
Also on record, not counted in the 75: 1 patent in force now held by others · 67 patents ended · 35 applications pending · 40 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.